Canadian Medical Device and PPE Sovereignty Act

⚠ This is a flightplan, not a commitment. Flightplans are hypothetical policy proposals modelled in the Ducklings causal simulation. They become projects only when voted into adoption through Consensus. Metrics shown reflect simulation model outputs, not real-world outcomes.

$0.60B CAD

Fiscal Impact

Long-term (5+ years)

Time Horizon

Medium

Implementation Risk

Epoch 97

Continuum Entry

Overview

Establish domestic content requirements and manufacturing incentives for critical healthcare supplies via a Critical Healthcare Supply List (CHSL). Four pillars: (1) CHSL designation of 50 product categories as national security requirements; (2) NPPA/NHLH domestic anchor contracts rising to 40% Canadian content by Year 8; (3) 35% ITC for CHSL manufacturing capital investment; (4) $300M API Development Fund for top 20 generic APIs currently imported exclusively from Asia.

Problem Statement

In 2020, Canada discovered 85% of N95 masks were manufactured in China, 60% of ventilator components in the US, and 70% of generic drug APIs in India and China. The COVID-19 pandemic disrupted all three simultaneously. Canada had no fallback. The lesson was clear and then ignored: by 2023, domestic PPE manufacturing briefly expanded during COVID had largely shuttered as procurement returned to lowest-cost offshore suppliers. The structural vulnerability was never addressed. Canada remains one emergency away from the same outcome.

Proposed Approach

Pillar 1: Health Canada designates Critical Healthcare Supply List (CHSL) of 50 categories as national security requirements (N95/surgical masks, gloves, gowns, ventilators, dialysis, insulin, epinephrine, generic antibiotics, 5 vaccine platform categories). Pillar 2: NPPA and NHLH required to source minimum 25% of CHSL from Canadian manufacturers within 3 years, rising to 40% by Year 8 — demand certainty enabling capital investment. Pillar 3: 35% Investment Tax Credit for capital investment in CHSL manufacturing; accelerated CCA (100% Year 1) for qualifying equipment. Pillar 4: $300M API Development Fund for domestic production of top 20 highest-volume generic APIs currently with no Canadian manufacturer.

Anticipated Impacts

domestic_ppe_production_share rises from 12% to 35-40% by Year 8; api_domestic_production_share rises from 8% to 20-25% by Year 8; drug_procurement_cost_index 88-94 (modest — domestic premium offset by reliability); healthcare_access rises to 90-94 resilience-adjusted; fdi_inflows +$2-4B from pharma/device manufacturers attracted by ITC; gdp_growth +0.1-0.15% manufacturing multiplier; imports_from_china -$2-3B structural reduction in device and API imports.

Ducklings Simulation

This proposal is active in the Ducklings causal simulation (Epoch 97). The simulation models downstream effects using a BFS cascade engine with strength-weighted, time-delayed edges capped at 3-hop depth and ±25% per-hop limits. Cascade outputs are bounded by variable saturation thresholds.

Domain: Healthcare | Proposal ID: 191 | Series: E-series

How to Engage

Discuss this flightplan in the Pond forum under Healthcare. Vote on adoption through Consensus. Adopted flightplans become projects with real-world implementation tracking.

Contact: [email protected]